-
Je něco špatně v tomto záznamu ?
Vancomycin pharmacokinetics in patients treated with intermittent haemodialysis based on therapeutic drug monitoring
JM. Hartinger, M. Šíma, K. Hronová, BA. Halouzková, B. Szonowská, V. Polakovič, V. Bednářová, Z. Hladinová, V. Tesař, O. Slanař
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
- MeSH
- antibakteriální látky MeSH
- dialýza ledvin MeSH
- lidé MeSH
- monitorování léčiv * MeSH
- poločas MeSH
- retrospektivní studie MeSH
- vankomycin * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Vancomycin is frequently used in haemodialysis (HD) patients but generally accepted target serum ranges and dosing strategy are still lacking in this group. Based on retrospective analysis of data from 118 HD patients treated with vancomycin the interdialytic elimination constant (Ke), apparent volume of distribution (Vd) and dialysis efficacy were calculated. The influence of possible clinical variables on the pharmacokinetic parameters of vancomycin have been tested. The median of Ke in interdialytic periods, corresponding half-life and Vd were 0.0073 h-1, 95.0 h and 0.87 L/kg, respectively. We found significant positive correlation between time in dialysis program and Ke. The Vd correlated best with lean body mass (LBM). For high- and low flux membrane HD of 4 hours duration the decline in vancomycin levels was 20.88% and 12.86%, respectively. Based on these data loading dose for vancomycin in HD patient should be calculated as 24.483 × LBM (kg) + 455 mg. The utility of this equation for entire HD population should be also verified prospectively.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018590
- 003
- CZ-PrNML
- 005
- 20240522101929.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/1120009X.2021.1979747 $2 doi
- 035 __
- $a (PubMed)34551680
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Hartinger, Jan $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0224709
- 245 10
- $a Vancomycin pharmacokinetics in patients treated with intermittent haemodialysis based on therapeutic drug monitoring / $c JM. Hartinger, M. Šíma, K. Hronová, BA. Halouzková, B. Szonowská, V. Polakovič, V. Bednářová, Z. Hladinová, V. Tesař, O. Slanař
- 520 9_
- $a Vancomycin is frequently used in haemodialysis (HD) patients but generally accepted target serum ranges and dosing strategy are still lacking in this group. Based on retrospective analysis of data from 118 HD patients treated with vancomycin the interdialytic elimination constant (Ke), apparent volume of distribution (Vd) and dialysis efficacy were calculated. The influence of possible clinical variables on the pharmacokinetic parameters of vancomycin have been tested. The median of Ke in interdialytic periods, corresponding half-life and Vd were 0.0073 h-1, 95.0 h and 0.87 L/kg, respectively. We found significant positive correlation between time in dialysis program and Ke. The Vd correlated best with lean body mass (LBM). For high- and low flux membrane HD of 4 hours duration the decline in vancomycin levels was 20.88% and 12.86%, respectively. Based on these data loading dose for vancomycin in HD patient should be calculated as 24.483 × LBM (kg) + 455 mg. The utility of this equation for entire HD population should be also verified prospectively.
- 650 _2
- $a antibakteriální látky $7 D000900
- 650 12
- $a monitorování léčiv $7 D016903
- 650 _2
- $a poločas $7 D006207
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dialýza ledvin $7 D006435
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a vankomycin $7 D014640
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Šíma, Martin $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/000000026541738X $7 xx0222901
- 700 1_
- $a Hronová, Karolína $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Halouzková, Barbora Agátha $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Szonowská, Barbora $u Internal Department of Strahov, General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Polakovič, Vladimír $u Internal Department of Strahov, General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Bednářová, Vladimíra $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Hladinová, Zuzana $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Tesař, Vladimír $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 773 0_
- $w MED00181505 $t Journal of chemotherapy $x 1973-9478 $g Roč. 34, č. 3 (2022), s. 149-156
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34551680 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20240522101925 $b ABA008
- 999 __
- $a ok $b bmc $g 1822270 $s 1169833
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 34 $c 3 $d 149-156 $e 20210923 $i 1973-9478 $m Journal of chemotherapy $n J Chemother $x MED00181505
- LZP __
- $a Pubmed-20220720
